|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
We investigated the effect of Abeta peptides on insulin binding to the insulin receptor because it is known that (1) Abeta and insulin are both amyloidogenic peptides sharing a common sequence recognition motif, (2) Abeta and insulin are substrates for the same insulin degrading enzyme, and (3) impaired glucose metabolism is a characteristic event in the pathology of AD.
|
12006603 |
2002 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
This review provides an overview of the IDE structure and function; a relationship is drawn between IDE, Type 2 Diabetes mellitus and Alzheimer's disease and the approaches that make IDE a potential target, are discussed.
|
24059320 |
2014 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
We have examined the relationship of lipid peroxidation (thiobarbituric acid-reactive substances; TBARS) and antioxidant capacity (Trolox-equivalent) to APOE status, Braak tangle stage, amyloid-β (Aβ) plaque load, and the concentration of soluble and insoluble forms of Aβ, post-synaptic and dendritic spine proteins PSD95 and drebrin, β-secretase and Aβ-degrading enzymes neprilysin (NEP), insulin-degrading enzyme (IDE), and angiotensin-converting enzyme (ACE), in frontal, temporal, and parietal cortex from AD and control brains.
|
20930272 |
2010 |
|
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We here report IDE gene promoter region variants that are associated with AD in subjects without an epsilon4 allele.
|
15181249 |
2004 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Moreover, we found that the levels of miR-7 are also elevated in brains of AD patients; this inversely correlates with the expression of its target genes IRS-2 and IDE.
|
31501273 |
2019 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
These new insights into the mechanisms of NEP and IDE regulation suggest possible pharmacological targets in developing AD therapies.
|
26376806 |
2016 |
|
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We investigated the association between two polymorphisms of IDE with AD in the Chinese population and found that the T/A genotype of rs4646958 had an important role in AD (adjusted p=0.007, odds ratio [OR]=2.796, 95% confidence interval [CI]=1.330-5.878), under the co-dominant genetic model.
|
22502914 |
2012 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Targeting the regulation of IDE may be a promising therapeutic approach to sporadic AD.
|
21873424 |
2011 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Although it is indispensable in removing plaques related to onset Alzheimer's disease (AD) and in degrading insulin related to diabetes, there have been few studies on the dynamic level of IDE in different stages of AD.
|
29680859 |
2018 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Among these, insulin-degrading enzyme (IDE) degrades amyloid-β peptide (Aβ), the core pathological product of Alzheimer's disease (AD), whereas β-amyloid cleavage enzyme 1 (BACE1) hydrolyzes amyloid-β protein precursor (AβPP).
|
31403945 |
2019 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Collectively, our data suggest that the genetic linkage of AD in this set of chromosome 10-linked AD families may be the result of systemic defects in IDE activity in the absence of altered IDE expression, further supporting a role for IDE in AD pathogenesis.
|
17244626 |
2007 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The findings suggest that IDE and RCAN1 differentially modulate brain insulin signaling in relation to AD severity and ApoE genotype.
|
31193223 |
2019 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Consequently, specific allosteric activation of IDE coupled with state-of-the-art compound delivery and CRISP-Cas9 technique of transgene insertion can be instrumental in the fight against AD and related neurodegenerative maladies.
|
29132916 |
2018 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We showed the decreased expression level of IDE and the activating of cAMP/PKA signaling pathway in AD and T2D mice.
|
28771808 |
2018 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Lower-expression of PS1 and over-expression of IDE or NEP may be helpful in potentially lowering brain Abeta levels in subjects with AD, and hence GEPT appears to offer potential that should be explored in AD.
|
19355846 |
2009 |
|
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
However, larger scale association studies are necessary to further validate the association of IDE polymorphisms with sporadic AD risk and to define potential gene-gene interactions.
|
23416320 |
2013 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recent studies suggest that insulin-degrading enzyme (IDE) in neurons and microglia degrades Abeta, the principal component of beta-amyloid and one of the neuropathological hallmarks of Alzheimer's disease (AD).
|
11125142 |
2000 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
As evidence indicates potential roles for IDE in diabetes and AD, understanding the mechanisms regulating IDE expression may be important in developing new treatment strategies.
|
29940507 |
2018 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Common Pesticide, Dichlorodiphenyltrichloroethane (DDT), Increases Amyloid-β Levels by Impairing the Function of ABCA1 and IDE: Implication for Alzheimer's Disease.
|
25720399 |
2015 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Membrane metalloendopeptidase (MME) and insulin-degrading enzyme (IDE) are two types of proteases that could cleave beta-amyloid (Aβ) peptides generated by neuron cells of AD patients.
|
31151136 |
2019 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
IDE is the common link between AD and Type II diabetes as insulin is an IDE target as well.
|
30338033 |
2018 |
|
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To determine the association between Alzheimer's disease in diabetic patients and the insulin degrading enzyme in outpatients of a second level Hospital in Monterrey, Mexico.
|
24355596 |
2015 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Herein, (i) In silico sequential and structural analysis of IDE and NEP has been performed to identify the molecular entities for proteolytic degradation of Aβ in the AD brain, (ii) to analyze their catalytic site to demonstrate the enzymatic action played by IDE and NEP, (iii) to identify their structural homologues that could behave as putative partners of IDE and NEP with similar catalytic action and (iv) to illustrate various IDE- and NEP-mediated therapeutic approaches and factors for clearing Aβ in AD.
|
26444774 |
2015 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Insulin-degrading enzyme (IDE) is a zinc metalloprotease that selectively degrades biologically important substrates associated with type 2 diabetes and Alzheimer's disease (AD).
|
30305381 |
2018 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Insulin-degrading enzyme and Alzheimer disease: a genetic association study in the Han Chinese.
|
15277615 |
2004 |